Relmada Secures $160 Million in PIPE Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RLMD?
Source: Newsfilter
- Significant Financing: Relmada Therapeutics announced a PIPE financing agreement expected to raise approximately $160 million, which will be utilized for the company's operations and R&D, reflecting strong market confidence in its innovative therapies.
- Share Sale Details: The financing involves the sale of 29,474,569 shares of common stock at a price of $4.75 per share, along with pre-funded warrants, expected to close on March 11, 2026, further strengthening the company's capital structure.
- Broad Investor Participation: The financing includes participation from notable investors such as Venrock Healthcare Capital Partners and Janus Henderson Investors, indicating a positive outlook on Relmada's future development from the market.
- Clear Strategic Use: Relmada intends to use the proceeds to advance its R&D projects in oncology and central nervous system areas, aiming to address significant unmet medical needs and enhance its competitiveness in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLMD
Wall Street analysts forecast RLMD stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.170
Low
9.00
Averages
9.50
High
10.00
Current: 7.170
Low
9.00
Averages
9.50
High
10.00
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xenon and Relmada Surge on Positive Drug Data
- Xenon Drug Breakthrough: Xenon Pharmaceuticals' azetukalner achieved a 53.2% reduction in seizure frequency in the Phase 3 X-TOLE2 study, with an NDA submission to the FDA targeted for the second half of 2026, significantly enhancing the company's commercialization prospects.
- Strong Financial Backing: Xenon currently holds $716 million in cash, providing a runway into the second half of 2027, which mitigates near-term financing risks and supports the new drug application process.
- Relmada Therapy Progress: Relmada Therapeutics' NDV-01 demonstrated a 92% complete response rate in 12-month data for non-muscle-invasive bladder cancer, with two Phase 3 trials expected to initiate in the first half of 2026, further solidifying its market position.
- Massive Market Potential: Relmada's NDV-01 is projected to achieve peak sales of $2.3 billion, with a current market cap of approximately $525 million, indicating strong growth potential that is attracting investor interest.
See More
Relmada Therapeutics to Participate in Healthcare Conference
- Conference Participation: Relmada Therapeutics' CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, showcasing the company's innovative therapies for oncology and CNS disorders.
- Event Schedule: The session is set to begin at 8:40 AM ET, with management also available for one-on-one investor meetings, aimed at strengthening connections with potential investors and enhancing the company's visibility in the capital markets.
- Webcast Access: The conference will be webcasted through the investor section of Relmada's website, allowing investors who cannot attend live to access an archived replay for 90 days post-event, ensuring key information is available to all stakeholders.
- Company Overview: Relmada Therapeutics focuses on developing transformative therapies for oncology and CNS conditions, with its lead candidates NDV-01 and sepranolone advancing through mid-stage clinical development to address significant unmet medical needs.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Relmada Therapeutics Reports Promising Interim Data for Bladder Cancer Treatment
- Clinical Trial Results: Relmada Therapeutics' NDV-01 demonstrated a complete response rate of 76% in its Phase 2 trial for bladder cancer, with an impressive 80% in the BCG-unresponsive patient population, indicating significant potential for patients with limited treatment options.
- High-Risk Patient Performance: The complete response rate for NDV-01 reached 95% at any time in high-risk bladder cancer patients and 94% in BCG-unresponsive patients, supporting the drug's advancement into the Phase 3 RESCUE registrational program, which aims to enhance clinical application.
- Convenient Administration: NDV-01 can be administered in under five minutes without anesthesia, which may facilitate its adoption in urology practices, and its favorable safety profile combined with high response rates positions it as a leading option for high-risk non-muscle invasive bladder cancer patients.
- Funding and Stock Performance: Relmada Therapeutics announced a private placement of approximately $160 million, selling around 29.5 million shares, while its stock surged 47.19% to $6.55 in premarket trading, marking a new 52-week high and reflecting strong market confidence in its future prospects.
See More
Relmada's Bladder Cancer Treatment Shows Promising Phase 2 Trial Results
- Clinical Trial Results: Relmada Therapeutics reported a 76% complete response (CR) rate at 12 months for its bladder cancer treatment NDV-01 in Phase 2 trials, achieving a remarkable 95% CR rate in high-risk non-muscle-invasive bladder cancer patients, indicating the drug's long-term efficacy and potential market value.
- Stock Price Surge: Following this positive update, Relmada's shares soared over 66% in pre-market trading on Monday, reflecting strong investor confidence in the company's future and high market recognition of its treatment approach.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Relmada Therapeutics trended bullish at the time of the announcement, suggesting that investor optimism about the company's prospects could further drive stock price increases.
- Industry Impact: This trial result not only enhances Relmada's reputation in the biopharmaceutical sector but may also attract more investor interest, boosting the company's competitiveness in the bladder cancer treatment market and accelerating its research and commercialization efforts.
See More
Relmada Secures $160 Million in PIPE Financing
- Significant Financing: Relmada Therapeutics announced a PIPE financing agreement expected to raise approximately $160 million, which will be utilized for the company's operations and R&D, reflecting strong market confidence in its innovative therapies.
- Share Sale Details: The financing involves the sale of 29,474,569 shares of common stock at a price of $4.75 per share, along with pre-funded warrants, expected to close on March 11, 2026, further strengthening the company's capital structure.
- Broad Investor Participation: The financing includes participation from notable investors such as Venrock Healthcare Capital Partners and Janus Henderson Investors, indicating a positive outlook on Relmada's future development from the market.
- Clear Strategic Use: Relmada intends to use the proceeds to advance its R&D projects in oncology and central nervous system areas, aiming to address significant unmet medical needs and enhance its competitiveness in the biotechnology sector.
See More
Xenon and Relmada Surge on Positive Drug Data
- Xenon Drug Breakthrough: Xenon Pharmaceuticals' azetukalner achieved a 53.2% reduction in seizure frequency in the Phase 3 X-TOLE2 study, with an NDA submission to the FDA targeted for the second half of 2026, significantly enhancing the company's commercialization prospects.
- Strong Financial Backing: Xenon currently holds $716 million in cash, providing a runway into the second half of 2027, which mitigates near-term financing risks and supports the new drug application process.
- Relmada Therapy Progress: Relmada Therapeutics' NDV-01 demonstrated a 92% complete response rate in 12-month data for non-muscle-invasive bladder cancer, with two Phase 3 trials expected to initiate in the first half of 2026, further solidifying its market position.
- Massive Market Potential: Relmada's NDV-01 is projected to achieve peak sales of $2.3 billion, with a current market cap of approximately $525 million, indicating strong growth potential that is attracting investor interest.
See More
Relmada Therapeutics to Participate in Healthcare Conference
- Conference Participation: Relmada Therapeutics' CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, showcasing the company's innovative therapies for oncology and CNS disorders.
- Event Schedule: The session is set to begin at 8:40 AM ET, with management also available for one-on-one investor meetings, aimed at strengthening connections with potential investors and enhancing the company's visibility in the capital markets.
- Webcast Access: The conference will be webcasted through the investor section of Relmada's website, allowing investors who cannot attend live to access an archived replay for 90 days post-event, ensuring key information is available to all stakeholders.
- Company Overview: Relmada Therapeutics focuses on developing transformative therapies for oncology and CNS conditions, with its lead candidates NDV-01 and sepranolone advancing through mid-stage clinical development to address significant unmet medical needs.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Relmada Therapeutics Reports Promising Interim Data for Bladder Cancer Treatment
- Clinical Trial Results: Relmada Therapeutics' NDV-01 demonstrated a complete response rate of 76% in its Phase 2 trial for bladder cancer, with an impressive 80% in the BCG-unresponsive patient population, indicating significant potential for patients with limited treatment options.
- High-Risk Patient Performance: The complete response rate for NDV-01 reached 95% at any time in high-risk bladder cancer patients and 94% in BCG-unresponsive patients, supporting the drug's advancement into the Phase 3 RESCUE registrational program, which aims to enhance clinical application.
- Convenient Administration: NDV-01 can be administered in under five minutes without anesthesia, which may facilitate its adoption in urology practices, and its favorable safety profile combined with high response rates positions it as a leading option for high-risk non-muscle invasive bladder cancer patients.
- Funding and Stock Performance: Relmada Therapeutics announced a private placement of approximately $160 million, selling around 29.5 million shares, while its stock surged 47.19% to $6.55 in premarket trading, marking a new 52-week high and reflecting strong market confidence in its future prospects.
See More
Relmada's Bladder Cancer Treatment Shows Promising Phase 2 Trial Results
- Clinical Trial Results: Relmada Therapeutics reported a 76% complete response (CR) rate at 12 months for its bladder cancer treatment NDV-01 in Phase 2 trials, achieving a remarkable 95% CR rate in high-risk non-muscle-invasive bladder cancer patients, indicating the drug's long-term efficacy and potential market value.
- Stock Price Surge: Following this positive update, Relmada's shares soared over 66% in pre-market trading on Monday, reflecting strong investor confidence in the company's future and high market recognition of its treatment approach.
- Market Sentiment Shift: Retail sentiment on Stocktwits regarding Relmada Therapeutics trended bullish at the time of the announcement, suggesting that investor optimism about the company's prospects could further drive stock price increases.
- Industry Impact: This trial result not only enhances Relmada's reputation in the biopharmaceutical sector but may also attract more investor interest, boosting the company's competitiveness in the bladder cancer treatment market and accelerating its research and commercialization efforts.
See More
Relmada Secures $160 Million in PIPE Financing
- Significant Financing: Relmada Therapeutics announced a PIPE financing agreement expected to raise approximately $160 million, which will be utilized for the company's operations and R&D, reflecting strong market confidence in its innovative therapies.
- Share Sale Details: The financing involves the sale of 29,474,569 shares of common stock at a price of $4.75 per share, along with pre-funded warrants, expected to close on March 11, 2026, further strengthening the company's capital structure.
- Broad Investor Participation: The financing includes participation from notable investors such as Venrock Healthcare Capital Partners and Janus Henderson Investors, indicating a positive outlook on Relmada's future development from the market.
- Clear Strategic Use: Relmada intends to use the proceeds to advance its R&D projects in oncology and central nervous system areas, aiming to address significant unmet medical needs and enhance its competitiveness in the biotechnology sector.
See More
